Molecular Targets for the Treatment of Metastatic Colorectal Cancer

被引：25

作者：

Cohen, Romain ^{[1
]}

Pudlarz, Thomas ^{[1
]}

Delattre, Jean-Francois ^{[1
]}

Colle, Raphael ^{[1
]}

Andre, Thierry ^{[1
]}

机构：

[1] Sorbonne Univ, Dept Med Oncol, Hop St Antoine, AP HP, F-75012 Paris, France

来源：

CANCERS | 2020年 / 12卷 / 09期

关键词：

colorectal cancer; NTRK; HER2; BRAF; microsatellite instability; ctDNA; MISMATCH REPAIR DEFICIENCY; EGFR MONOCLONAL-ANTIBODIES; KRAS WILD-TYPE; CETUXIMAB PLUS IRINOTECAN; PHASE-III TRIAL; COLON-CANCER; POOLED ANALYSIS; BRAF MUTATION; 1ST-LINE TREATMENT; MICROSATELLITE INSTABILITY;

D O I：

10.3390/cancers12092350

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI),RASandBRAFmutations,HER2amplification orNTRKfusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI,HER2,NTRK).

引用

页码：1 / 18

页数：17

共 123 条

[1] Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 [J].

Allegra, Carmen J. ;

Rumble, R. Bryan ;

Hamilton, Stanley R. ;

Mangu, Pamela B. ;

Roach, Nancy ;

Hantel, Alexander ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02) :179-+

[2] miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial [J].

Anandappa, Gayathri ;

Lampis, Andrea ;

Cunningham, David ;

Khan, Khurum H. ;

Kouvelakis, Kyriakos ;

Vlachogiannis, Georgios ;

Hedayat, Somaieh ;

Tunariu, Nina ;

Rao, Sheela ;

Watkins, David ;

Starling, Naureen ;

Braconi, Chiara ;

Darvish-Damavandi, Mahnaz ;

Lote, Hazel ;

Thomas, Janet ;

Peckitt, Clare ;

Kalaitzaki, Ria ;

Khan, Nasir ;

Fotiadis, Nicos ;

Rugge, Massimo ;

Begum, Ruwaida ;

Rana, Isma ;

Bryant, Annette ;

Hahne, Jens C. ;

Chau, Ian ;

Fassan, Matteo ;

Valeri, Nicola .

CLINICAL CANCER RESEARCH, 2019, 25 (13) :3830-3838

[3] Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study [J].

Andre, T. ;

Blons, H. ;

Mabro, M. ;

Chibaudel, B. ;

Bachet, J-B. ;

Tournigand, C. ;

Bennamoun, M. ;

Artru, P. ;

Nguyen, S. ;

Ebenezer, C. ;

Aissat, N. ;

Cayre, A. ;

Penault-Llorca, F. ;

Laurent-Puig, P. ;

de Gramont, A. .

ANNALS OF ONCOLOGY, 2013, 24 (02) :412-419

[4] Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [J].

Andre, Thierry ;

de Gramont, Armand ;

Vernerey, Dewi ;

Chibaudel, Benoist ;

Bonnetain, Franck ;

Tijeras-Raballand, Annemilai ;

Scriva, Aurelie ;

Hickish, Tamas ;

Tabernero, Josep ;

Van Laethem, Jean Luc ;

Banzi, Maria ;

Maartense, Eduard ;

Shmueli, Einat ;

Carlsson, Goran U. ;

Scheithauer, Werner ;

Papamichael, Demetris ;

Moeehler, Marcus ;

Landolfi, Stefania ;

Demetter, Pieter ;

Colote, Soudhir ;

Tournigand, Christophe ;

Louvet, Christophe ;

Duval, Alex ;

Flejou, Jean-Francois ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) :4176-+

[5]

[Anonymous], 2020, J CLIN ONCOL S

[6]

[Anonymous], 2019, J CLIN ONCOL S

[7]

[Anonymous], 2019, J CLIN ONCOL S

[8]

[Anonymous], 2020, J CLIN ONCOL S

[9]

[Anonymous], 2015, ASCO M S

[10]

[Anonymous], 2020, J CLIN ONCOL S

← 1 2 3 4 5 6 7 8 9 10 →